Key result
Acute RRT manages refractory AKI and cardiorenal syndrome, but high mortality and dialysis risks persist.
Answers are grounded in this paper and cite their sources.
This review provides an overview of the management of severe AKI and refractory cardiorenal syndrome, emphasizing the indications and multidisciplinary management of acute renal replacement therapies in the cardiac intensive care unit.
Acute kidney injury (AKI) and cardiorenal syndrome (CRS) are increasingly prevalent in hospitalized patients with cardiovascular disease and remain associated with poor short- and long-term outcomes. There are no specific therapies to reduce mortality related to either AKI or CRS, apart from supportive care and volume status management. Acute renal replacement therapies (RRTs), including ultrafiltration, intermittent hemodialysis, and continuous RRT are used to manage complications of medically refractory AKI and CRS and may restore normal electrolyte, acid-base, and fluid balance before renal recovery. Patients who require acute RRT have a significant risk of mortality and long-term dialysis dependence, emphasizing the importance of appropriate patient selection. Despite the growing use of RRT in the cardiac intensive care unit, there are few resources for the cardiovascular specialist that integrate the epidemiology, diagnostic workup, and medical management of AKI and CRS with an overview of indications, multidisciplinary team management, and transition off of RRT.
No takes yet. Share an insight, caveat, or question.
Jentzer et al. (2020) conducted a review in Severe Acute Kidney Injury and Refractory Cardiorenal Syndrome. Acute renal replacement therapies was evaluated. Acute renal replacement therapies are used to manage medically refractory acute kidney injury and cardiorenal syndrome, though patients remain at significant risk of mortality and dialysis dependence.
Synapse has enriched 10 related papers. Consider them for comparative context: